1. Scrip
  2. >>Scrip Asks

Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet

Industry Leaders Share Their Equity And Sustainability Aspirations

 
• By Eleanor Malone

Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.  

Scrip Asks, Part 7
• Source: Alamy

The final installation of our series looking at industry leaders’ expectations for the year ahead focuses on sustainability and equity: in health care, in companies and across society as a whole.

Tom Oakley, CEO of medical imaging software and systems specialist Feedback plc, summed up a broad perspective shared by several of his peers that the time for radical change has come when he said that “2022 is going to be a year of opportunity for change, an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

More from Scrip

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.